ReviewJournal of fungi (Basel, Switzerland)2021
Epidemiology of Systemic Mycoses in the COVID-19 Pandemic.
Review in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Pooled it
- Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.American journal of respiratory and critical care medicine · 2025Article
- Invasive Candidiasis Coinfection in Patients with Severe COVID-19 Disease: Scoping Review.Pathogens (Basel, Switzerland) · 2025Article
- A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile.PloS one · 2025Article
- Fungal coinfection/superinfection in COVID-19 patients in a tertiary hospital in MexicoBiomedica : revista del Instituto Nacional de Salud · 2024Article
- Molecular detection ofEpidemiology and infection · 2024Article
- Identifying the risk factors of ICU-acquired fungal infections: clinical evidence from using machine learning.Frontiers in medicine · 2024Article
- Discovery of a new chemical scaffold for the treatment of superbugEmerging microbes & infections · 2023Article
- Associated Bacterial Coinfections in COVID-19-Positive Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Meningeal cryptococcosis and SARS-CoV-2 infection in people living with HIV/AIDS.Biomedica : revista del Instituto Nacional de Salud · 2023Article
- Lower Concentrations of Amphotericin B Combined withAntibiotics (Basel, Switzerland) · 2023Article
- Non-Mucormycetes Causes of Fungal Rhino Sinusitis With Periocular Swelling in COVID-19 With Delta Variant.Cureus · 2022Article
- COVID-19-associated opportunistic infections: a snapshot on the current reports.Clinical and experimental medicine · 2022Review
- Repurposing and optimization of drugs for discovery of novel antifungals.Drug discovery today · 2022Review
- COVID-19-associated facial cutaneous mucormycosis superinfection: A potentially life-threatening disease.Clinical case reports · 2022Article
- Current Landscape of Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Invasive fusariosis in a critically ill patient with severe COVID-19 pneumonia: A case report.Medical mycology case reports · 2022Article
- Does the Fetus Limit Antibiotic Treatment in Pregnant Patients with COVID-19?Antibiotics (Basel, Switzerland) · 2022Article
- Fungal Colonization and Infections-Interactions with Other Human Diseases.Pathogens (Basel, Switzerland) · 2022Review
- Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.Mycoses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The physiopathologic characteristics of COVID-19 (high levels of inflammatory cytokines and T-cell reduction) promote fungal colonization and infection, which can go unnoticed because the symptoms in both diseases are very similar. The objective of this work was to study the current epidemiology of systemic mycosis in COVID-19 times. A literature search on the subject (January 2020-February 2021) was performed in PubMed, Embase, Cochrane Library, and LILACS without language restrictions. Demographic data, etiological agent, risk factors, diagnostic methods, antifungal treatment, and fatality rate were considered. Eighty nine publications were found on co-infection by COVID-19 and pneumocystosis, candidiasis, aspergillosis, mucormycosis, coccidioidomycosis, or histoplasmosis. In general, the co-infections occurred in males over the age of 40 with immunosuppression caused by various conditions. Several species were identified in candidiasis and aspergillosis co-infections. For diagnosis, diverse methods were used, from microbiological to molecular. Most patients received antifungals; however, the fatality rates were 11-100%. The latter may result because the clinical picture is usually attributed exclusively to SARS-CoV-2, preventing a clinical suspicion for mycosis. Diagnostic tests also have limitations beginning with sampling. Therefore, in the remainder of the pandemic, these diagnostic limitations must be overcome to achieve a better patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.